RxDoctor Payments Data

Kevin McMullen, MD

Dermatology · Missoula, MTNPI 1225442247

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $825 of the $925 with a category attached, or 89.2%. 12 manufacturers reported payments, led by Johnson & Johnson at 28.3% of the total. 2025 is the largest year on record at $481, more than ten times the $25 reported in 2019. That places this record below the midpoint for dermatology clinicians in MT, where the typical reported total is $1,595.

$925in general payments, 2019–2025

Across 47 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$262
  • Amgen$127
  • LEO Pharma Inc.$116
  • UCB, Inc.$111
  • AbbVie$77
  • Novartis$72
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$82589%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson11$262
Amgen8$127
LEO Pharma Inc.5$116
UCB, Inc.6$111
AbbVie4$77
Novartis3$72
Incyte Corporation4$65
Sanofi2$30
Genentech USA, Inc.1$25
Lilly USA, LLC1$18
E.r. Squibb & Sons, L.L.C.1$14
Biowound Solutions, Inc.1$8

How this compares

$925 in reported general payments places this provider in the 40th percentile of 46 dermatology providers in Montana.

See all dermatology providers in Montana

Medicare billing

Part B allowed, 2024
$314,510
Medicare patients
1,183
Services billed
6,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$58,800
LitfuloRitlecitinib Tosylate14$56,339
Clobetasol Propionate70$2,910
Fluocinonide54$1,718
Ketoconazole86$1,209
Triamcinolone Acetonide118$876
ValacyclovirValacyclovir Hcl28$643
Hydroxychloroquine Sulfate17$561
Doxycycline Hyclate19$503
Mupirocin24$331
Hydrocortisone72$319
Spironolactone15$279
Minoxidil29$227
Prednisone13$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$127$58,80012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 46 dermatology providers in Montana.

Other dermatology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →